DiagnosticsObjective: This study aimed to establish a correlation between fecal calprotectin levels (FC) and intestinal inflammation in patients with spondyloarthritis without inflammatory bowel disease.
Juliette De Avila +14 more
doaj +1 more source
ACR Open Rheumatology, Volume 8, Issue 5, May 2026.Objective Proadrenomedullin (pro‐ADM) is a peptide implicated in immunomodulation, with higher levels observed in inflammatory conditions, cardiovascular impairment, and sepsis. Although extensively studied in acute disorders, its potential as a biomarker in inflammatory arthritis remains underexplored.
Nefeli Stavroula Papastathopoulou +10 more
wiley +1 more source
Spondyloarthritis Associated With Collagenous Colitis—Case Report and Literature Review
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Collagenous colitis (CC) is a subtype of microscopic colitis characterized by chronic watery diarrhea with normal endoscopic findings. Although often linked to autoimmune diseases, its association with spondyloarthropathy (SpA) is rare and poorly documented.
Charlotte Bouvy +4 more
wiley +1 more source
Primary or Secondary Synostosis: The Culmination of the Spondyloarthritis Form of Erosive Arthritis? [PDF]
, 2015 Bruce M. Rothschild
openalex +1 more source
Sa1842 FACTORS ASSOCIATED WITH REMISSION OF AXIAL SPONDYLOARTHRITIS AT ONE YEAR AFTER INITIATION OF ANTI-TUMOR NECROSIS FACTOR AGENTS AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES [PDF]
, 2023 Rahul S. Dalal +4 more
openalex +1 more source
ReumatismoSpondyloarthritis is an umbrella term for a heterogeneous group of chronic inflammatory diseases affecting the spine and/or peripheral joints, often associated with extra-articular manifestations, such as psoriasis, uveitis, and inflammatory bowel disease...
Ramonda, R, Oliviero, F
openaire +4 more sources
Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley +1 more source
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 887-899, May 2026.This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
AB0157C OCULAR CAUSES OF THE INITIATION OF SYSTEMIC THERAPYIN PATIENTS WITH SPONDYLOARTHRITIS (SPA) AND UVEITIS [PDF]
, 2019 M. Garijo Bufort +4 more
openalex +1 more source
SAT0645 ANTI-DFS70 AUTOANTIBODIES INDUCED BY ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS [PDF]
, 2019 Teresa Carbone +8 more
openalex +1 more source